Business
Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights
DUBLIN, February 19, 2026--Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights
About this update from Prothena Corporation Plc
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":3612,"height":1160,"url":"https://media.zenfs.com/en/business-wire.com/6fdd6e2cab2b789aa736c86e296807ca"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Q.o3YynE59ud0_y0OKjEpQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMwODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/6fdd6e2cab2b789aa736c86e296807ca","width":960,"height":308},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/6KuARYFTM6b6iMFFjseTGg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD03NzA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/6fdd6e2cab2b789aa736c86e296807ca","width":1200,"height":385}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Net cash used in operating and investing activities was $23.3 million and $163.7 million for the fourth quarter and full year of 2025, respectively; quarter-end cash and restricted cash position was $308.4 million","length":213,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Prothena expects the full year 2026 net cash used in operating and investing activities to be $50 to $55 million and expects to end the year with approximately $255 million in cash (midpoint). Financial guidance does not include the potential to earn up to $105 million in aggregate clinical milestone payments from strategic partners in 2026","length":342,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Roche initiated the Phase 3 PARAISO trial evaluating prasinezumab in early-stage Parkinson’s disease in 4Q 2025; primary completion expected in 2029","length":148,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Novo Nordisk initiated the Phase 3 CLEOPATTRA trial evaluating coramitug in ATTR amyloidosis with cardiomyopathy in 4Q 2025; primary completion expected in 2029","length":160,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Bristol Myers Squibb fully enrolled the Phase 2 TargetTau-1 trial evaluating BMS-986446 in early Alzheimer’s disease with primary completion expected in 1H 2027, completed a Phase 1 trial evaluating a subcutaneous formulation of BMS-986446 and obtained Fast Track designation from the U.S. FDA for BMS-986446 for the treatment of Alzheimer’s disease","length":349,"tagName":"p","attribs":{}}]},{"val":[{"type":"tex...